Suppr超能文献

三种L.对慢性阻塞性肺疾病患者的疗效和安全性:一项系统评价和荟萃分析。

Efficacy and safety of three species of L. in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis.

作者信息

Yu Haichuan, Lei Ting, Su Xiaojie, Zhang Lu, Feng Zhouzhou, Dong Mengya, Hou Zheyu, Guo Hong, Liu Jian

机构信息

Clinical Medicine Department, First Medical College, Lanzhou University, Lanzhou, China.

Critical Care Department, The First Hospital of Lanzhou University, Lanzhou, China.

出版信息

Front Pharmacol. 2023 Apr 6;14:1139239. doi: 10.3389/fphar.2023.1139239. eCollection 2023.

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by chronic hypoxia, inflammation, oxidative stress, and irreversible airflow limitations. L is a genus of botanical drugs used in traditional medicine that may influence COPD. A systematic review of the safety and efficacy of L. in patients with COPD. We searched the PubMed, Embase, Cochrane Library, Web of Science, Scopus, China National Knowledge Infrastructure (CNKI), Chongqing VIP, Wanfang, and SinoMed databases. The search strategy used terms including "COPD" and "Rhodiola." Two independent reviewers conducted the literature screening, data extraction, and risk of bias assessment, with a third reviewer involved to resolve disagreements. Statistical analysis was conducted in Review Manager (version 5.4.1), following the Cochrane Handbook. This review included nine studies, of which two focused on (Hook.f. and Thomson) H. Ohba (R. ) and two on (Regel) Maxim (R. ); the remaining five focused on (Hook.) S.H.Fu (R. ). Compared with the placebo, patients who received L. presented no more adverse events ( = 0.65) but showed significant improvement in the percentage of forced expiratory volume in 1 s at prediction (FEV1%pred), forced expiratory volume in 1 s (FEV1), the ratio of forced expiratory volume in 1 s on forced vital capacity (FEV1/FVC), saturation of oxygen in arterial blood, partial pressure of oxygen in arterial blood (PaO), partial pressure of carbon dioxide in arterial blood (PaCO), systolic pulmonary arterial pressure, diastolic pulmonary arterial pressure, COPD assessment test, efficient rate, C-reactive protein, and N-terminal pro-B-type natriuretic peptide (all < 0.01). Compared with ambroxol, R. provided additional benefits to patients with COPD in FEV1%pred, FEV1, FEV1/FVC, PaO2, PaCO2, 8-iso-prostaglandin F2α, superoxide dismutase, glutathione, malondialdehyde, and total antioxidant capacity (all < 0.01). Among the L. genus, this review included R. , R. , and R. , which might be safe and effective in COPD. Although this study has several limitations, further RCTs are needed. : [https://www.crd.york.ac.uk/PROSPERO/ display_record.php?RecordID=302881], identifier [CRD42022361890].

摘要

慢性阻塞性肺疾病(COPD)的特征是慢性缺氧、炎症、氧化应激和不可逆的气流受限。红景天属是一类用于传统医学的植物药,可能对COPD有影响。对红景天属植物在COPD患者中的安全性和有效性进行系统评价。我们检索了PubMed、Embase、Cochrane图书馆、Web of Science、Scopus、中国知网(CNKI)、重庆维普、万方和中国生物医学文献数据库。检索策略使用了包括“COPD”和“红景天”在内的检索词。两名独立的评价者进行文献筛选、数据提取和偏倚风险评估,第三名评价者参与解决分歧。按照Cochrane手册,在Review Manager(5.4.1版)中进行统计分析。本综述纳入了9项研究,其中2项聚焦于大花红景天(Rhodiola crenulata (Hook.f. and Thomson) H. Ohba),2项聚焦于库页红景天(Rhodiola sachalinensis (Regel) Maxim);其余5项聚焦于狭叶红景天(Rhodiola kirilowii (Hook.) S.H.Fu)。与安慰剂相比,接受红景天属植物治疗的患者不良事件发生率无差异(P = 0.65),但在预测的1秒用力呼气量百分比(FEV1%pred)、1秒用力呼气量(FEV1)、1秒用力呼气量与用力肺活量之比(FEV1/FVC)、动脉血氧饱和度、动脉血氧分压(PaO₂)、动脉血二氧化碳分压(PaCO₂)、收缩期肺动脉压、舒张期肺动脉压、COPD评估测试、有效率、C反应蛋白和N末端B型利钠肽原(均P < 0.01)方面有显著改善。与氨溴索相比,大花红景天在FEV1%pred、FEV1、FEV1/FVC、PaO₂、PaCO₂、8-异前列腺素F2α、超氧化物歧化酶、谷胱甘肽、丙二醛和总抗氧化能力方面为COPD患者提供了额外益处(均P < 0.01)。在红景天属植物中,本综述纳入了大花红景天、库页红景天和狭叶红景天,它们在COPD中可能是安全有效的。尽管本研究有一些局限性,但仍需要进一步的随机对照试验。网址:[https://www.crd.york.ac.uk/PROSPERO/ display_record.php?RecordID=302881],标识符[CRD42022361890]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bbd9/10117638/911ed69cb0dc/fphar-14-1139239-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验